Medivir Plans For A Post-Simeprevir Future
The hepatitis C therapy simeprevir may have been a commercial success for the small Swedish biotech Medivir, but as competition increases and sales decline, the company is planning for what comes next.
The hepatitis C therapy simeprevir may have been a commercial success for the small Swedish biotech Medivir, but as competition increases and sales decline, the company is planning for what comes next.